Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 19/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.69 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442674 | 0.90 | HRH4 (0.68) | HRH4HRH3HTR3ATP53MAPT | |
| SCHEMBL2470171 | 0.87 | HRH4 (0.53) | HRH4HRH3TP53MAPTSMN1; SMN2 | |
| SCHEMBL2463274 | 0.86 | HRH4 (0.53) | HRH4HRH3TP53MAPTSMN1; SMN2 | |
| SCHEMBL2535746 | 0.86 | HRH4 (0.63) | HRH4HRH3HTR3ATP53MAPT | |
| SCHEMBL12225204 | 0.85 | HRH4 (0.68) | HRH4HRH3HTR3ATP53MAPT | |
| SCHEMBL2467126 | 0.83 | HRH4 (0.67) | HRH4HRH3HTR3A | |
| SCHEMBL342005 | 0.83 | HRH4 (0.71) | HRH4HRH3HTR3ATP53MAPT | |
| SCHEMBL14828783 | 0.82 | HRH4 (1.00) | HRH4HRH3HTR3A | |
| SCHEMBL12245647 | 0.82 | HRH4 (0.48) | HRH4HRH3TP53MAPTSMN1; SMN2 | |
| SCHEMBL2489323 | 0.81 | HRH4 (0.51) | HRH4HRH3HTR3ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885HTR3A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.